Cadrenal Therapeutics has acquired VLX-1005, a first-in-class Phase 2 12-LOX inhibitor, along with related assets from Veralox Therapeutics. The addition of VLX-1005 bolsters Cadrenal's pipeline with a novel therapeutic candidate for the treatment of heparin-induced thrombocytopenia $(HIT)$, a serious condition lacking therapies that target its immune-driven biology. VLX-1005 is the first and only potent, highly selective inhibitor of human 12-LOX in clinical testing and has received Orphan Drug and Fast Track designations from the FDA. Under the terms of the agreement, Veralox will receive upfront and milestone payments, as well as royalties on future global sales.